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Abstract 
Epithelial ovarian cancer (EOC) frequently metastasizes to the omentum, a process 
that requires pro-angiogenic activation of human omental microvascular endothelial 
cells (HOMECs) by tumour-secreted factors.  We have previously shown that ovarian 
cancer cells secrete a range of factors that induce pro-angiogenic responses e.g. 
migration, in HOMECs including the lysosomal protease cathepsin D (CathD). 
However, the cellular mechanism by which CathD induces these cellular responses is 
not understood. The aim of this study was to further examine the pro-angiogenic 
effects of CathD in HOMECs i.e. proliferation and migration, to investigate whether 
these effects are dependent on CathD catalytic activity and to delineate the 
intracellular signalling kinases activated by CathD. We report, for the first time, that 
CathD significantly increases HOMEC proliferation and migration via a non-proteolytic 
mechanism resulting in activation of   ERK1/2 and AKT. These data suggest that EOC 
cancer secreted CathD acts as an extracellular ligand and may play an important pro-
angiogenic, and thus pro-metastatic, role by activating the omental microvasculature 
during EOC metastasis to the omentum.  
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1. Introduction 
Epithelial ovarian cancer (EOC) is the most lethal of all gynaecological cancers. 
Annually, approximately 200,000 women are diagnosed with this malignancy 
worldwide, resulting in 125,000 disease related deaths each year [1]. Initial symptoms 
are often vague, frequently leading to advanced disease with widespread metastases 
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at diagnosis which is therapeutically challenging [2]. As a result, 5 year survival is still 
only approximately 45% [3].  
EOC primarily metastasises via the transcoelomic route, with cancer cells 
disseminating within the peritoneum to form secondary foci.  The omentum is a 
common initial point of spread, with omental invasion facilitating more widespread 
metastasis [4]. In order to establish a secondary tumour within the omentum ovarian 
cancer cells must attach to the mesothelium, invade the omental tissue and then 
initiate angiogenesis i.e. sprouting of new blood vessels from the pre-existing vascular 
bed, to sustain secondary tumour growth. This process requires a complex interplay 
between tumour and resident cells, with secretion of growth factors and chemokines 
that ultimately leads to activation of a pro-angiogenic phenotype in the omental 
microvascular endothelial cells (ECs) and subsequently neovascularisation [5-9].  
Vascular endothelial growth factor A (VEGFA) is known to be a major pro-angiogenic 
stimulator in many tumour types and both VEGFA expression and secretion are known 
to be upregulated in EOC [10, 11].  However, our previous studies have indicated that 
angiogenic changes in the omental ECs during metastasis of ovarian cancer to the 
omentum are primarily driven by alternative pro-angiogenic factors secreted by EOC 
cells [12].  These data are supported by the observation that anti-VEGFA therapy 
(bevacizumab) has shown limited efficacy in patients with ovarian cancer [13], 
highlighting the need for a clearer understanding of the pro-angiogenic pathways 
involved.  
One of the alternative pro-angiogenic proteins we previously identified is cathepsin D 
(CathD), an aspartic endopeptidase, typically involved in degrading unfolded, 
dysfunctional self- or foreign- proteins in lysosomes and phagosomes [14]. Although 
CathD is a lysosomal enzyme and its enzyme activity is usually regulated within the 
acidic compartment of lysosomes, it has also been reported to be secreted via, an as 
yet, unknown mechanism.  Physiologically, CathD has been found in human, bovine 
and rat milk and serum [15-18], and pathophysiologically overexpression and 
hypersecretion of CathD has been demonstrated in a variety of cancers  including 
ovarian,  breast, endometrial, lung and prostate, as well as malignant glioma and 
melanoma [12, 19-32]. Indeed, we have detected CathD in the secretome of EOC cells 
in vitro [12], in ascites of patients suffering from ovarian cancer (unpublished data) and 
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have shown that there is a significantly higher expression of CathD in omentum of 
patients with metastasised serous ovarian carcinoma compared with omentum from 
patients with benign ovarian cystadenoma [33].   
There is increasing evidence that extracellular CathD may play a role in tumour 
angiogenesis including in metastasis of ovarian cancer to the omentum.  In the wider 
cancer field CathD increases tumour vascularity in tumour xenografts in mice [18] and 
enhances angiogenesis in a chick chorioallontoic membrane model (CAM) [34], 
induces pro-angiogenic changes in more than one type of EC [12,34],  as well as 
inducing degradation of extracellular matrix (ECM) components and release of growth 
factors such as basic fibroblast growth factor (bFGF) [22], and proliferation of cancer 
cells [35-39] and fibroblasts [40].  In relation to omental metastasis exogenous CathD 
induces pro-angiogenic cellular effects on disease relevant human omental 
microvascular ECs (HOMECs) e.g.  enhanced migration structures [12] and as 
mentioned above is overexpressed in the omentum of patients with metastasised EOC 
[33].    
Interestingly, although lysosomal CathD has proteolytic functions, secreted CathD has 
been reported to be active in both a proteolytic and non-proteolytic manner. For 
instance, both wild-type and mutated (ASN 231, proteolytically inactive) CathD 
stimulate proliferation of 3Y1-Ad12 rat tumour cells in athymic nude mice [36].  
Additionally, CathD can act as a protein ligand to induce proliferation of fibroblasts [40] 
and MCF7 breast cancer cells [22, 41].  A pro-angiogenic role for non-proteolytically 
active CathD has been demonstrated in studies using pepstatin A, a specific inhibitor 
of CathD-proteolytic activity, which inhibited CathD-induced migration and tube 
formation both in cultured human umbilical vein ECs and angiogenesis in a CAM 
model [34].  
Despite the emerging role for CathD in tumour growth, and the data described above 
suggesting specific involvement of extracellular CathD in angiogenesis in secondary 
omental lesions of EOC, the downstream cell signalling pathways activated by the 
protein are still poorly understood and remain to be elucidated.  Given the therapeutic 
challenges posed by EOC a fuller understanding of the processes involved in 
secondary tumour formation may aid development of treatment strategies. We have 
previously published a technique for isolating disease relevant HOMECs [42] and in 
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this study we used this cell model to (a) investigate whether CathD exerts its migratory 
and/or proliferative effects through a proteolytic or non-proteolytic mechanism and (b) 
the downstream signalling cascades activated by CathD.  We demonstrate, for the first 
time that CathD significantly increases HOMEC proliferation and migration via 
proteolytic-independent mechanisms. Importantly, we also show that exogenous 
CathD activates the intracellular kinases ERK1/2 and AKT (S473) as part of a 
signalling cascade that ultimately induces a proliferative and migratory phenotype in 
HOMECs.  
 
2. Materials and methods 
2.1. Primary cell culture 
Non-malignant omental tissue samples were collected from patients undergoing 
surgery at the Royal Devon and Exeter NHS Foundation Trust (Exeter, United 
Kingdom) with ethical approval and informed written consent. HOMECs were isolated, 
characterised and cultured as primary cells as previously described [42]. Briefly, 
HOMECs were cultured in endothelial cell growth media (MV2, PromoCell, Heidelberg, 
Germany) supplemented with supplied growth factors, 5% (v/v) foetal calf serum 
(FCS) and 0.1% (v/v) gentamycin (Sigma, Poole, UK). Cells were maintained at 37°C 
in a humidified atmosphere supplemented with 5 % CO2.  
2.2. Cell proliferation assay 
HOMEC proliferation was assessed using the WST-1 water soluble tetrazolium salt-1 
assay (Roche, Welwyn Garden City, UK). Cells were seeded at a density of 1x104 cells 
per well in 2% (w/v) gelatin (Sigma, Poole, UK) coated 96-well plates (Greiner Bio 
One, Stonehouse, UK) and treated overnight in growth factor-deprived media 
containing 2% (v/v) FCS. After 24 hours, treatments (CathD, VEGF as positive control 
± inhibitors) were added at the given concentrations (Table 1) and incubated for 72 
hours. Subsequently, WST-1 reagent was added in a 1:10 dilution to the assay 
medium for 2 hours incubation and absorbance was measured at 450 nm against the 
blank in PHERAstar BMG plate-reader.  Based on the data obtained 50ng/ml CathD 
was determined to be optimal for proliferation and this concentration was used for all 
subsequent experiments unless otherwise noted. 
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2.3. pH experiments 
2.3.1. Measurement of pH of cell culture media during cell culture 
HOMECs were seeded at a density of 3x105 cells per well in 6 well plates, based on 
preliminary optimization experiments. After overnight incubation in growth factor 
depleted media as above, fresh media supplemented ± CathD (50ng/ml) was added. 
Culture media was collected and pH was measured after 24, 48 and 72 hours using 
an ABL80 FLEX blood-gas analyser (Radiometer, Crawley, UK). pH of medium-only 
was also measured at the beginning of incubation period. 
2.3.2 Measurement of enzymatic activity of CathD at different pHs 
CathD proteolytic activity was measured using a CathD-specific fluorogenic substrate 
Mca-Gly-Lys-Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2, (100 nmol/l, Enzo 
Life Sciences, Exeter, UK,), in the presence or absence of pepA (1 µmol/l) in black 
opaque 96-well plates (Greiner Bio One, Stonehouse, UK). Prepared buffer solutions 
at specific pHs containing substrate ± pepA were added to the wells (100µl). 
Subsequently, 20µl of 50ng/ml CathD was added as required to make up the final 
volume of 120µl. Control wells contained substrate or substrate and pepA, and 20µl 
of corresponding pH buffer solution. The plate was shaken for 60 seconds in a plate-
reader immediately prior to fluorescence reading at Ex/Em: 320/393.  The experiment 
was performed away from direct light exposure. The pH buffer solutions were prepared 
by mixing citric acid monohydrate and Na2HPO4 solutions and 0.005% (v/v) Tween 20 
(Sigma-Aldrich, Poole, UK) in the correct proportions to ensure a final pH of: 3, 3.6, 4, 
4.6, 5, 5.6, 6, 6.6, 7 and 7.6 (supplementary data). 
2.4. Detection of phosphorylation of intracellular signalling intermediates 
2.4.1. Phosphokinase array 
Upregulation of phosphorylation of intracellular kinases was detected using a 
Proteome Profiler Human Phospho-Kinase Array kit (R&D Systems, Abingdon, UK), 
according to the manufacturer’s instructions. Briefly, HOMECs were seeded in 10cm2 
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petri dishes and cultured as above until confluent. Cells were starved overnight and 
then treated ± 50ng/ml CathD, ± inhibitors as detailed, for 4 minutes and subsequently 
lysed. A BCA protein assay was performed to quantify the total protein levels in each 
lysate. Controls received carrier alone. 200µg of protein (lysate) was incubated with 
antibody coated membranes and levels of phosphorylated proteins were assessed by 
chemiluminescence detected on film. The relative expression of specific 
phosphorylated proteins was determined following quantification of spot density on 
scanned images by Image-J. The results are expressed as mean dot density (arbitrary 
units). 
2.4.2. Cell based ELISA 
Phosphorylation levels of ERK1/2 and AKT were measured using specific cell-based 
ELISA kits (R&D Systems, Abingdon, UK) according to the manufacturer’s 
instructions. Cells were treated ± VEGF (20ng/ml, positive control) and CathD 
(50ng/ml) in the presence or absence of ERK1/2 and AKT inhibitors at their given 
concentrations (Table 1) for 4 and/or 10 minutes. Phosphorylation was examined at 
two time points since activation of intracellular kinases can be transient [43]. The 
shorter time point (4 minutes) for CathD was selected because previous reports 
suggest that MAPK/ERK1/2 and AKT phosphorylation are maximum at 4-5 minutes 
[44]. Fluorescence intensity was measured and the results are expressed as fold 
change in phospho-ERK1/2 or -AKT relative to total ERK or AKT levels (compared to 
control).  
2.5. HOMEC migration 
Cell migration was assessed using a Cultrex Cell 96 transwell migration assay (R&D 
Systems, Abingdon, UK) as per kit instructions. Briefly, cells were grown in growth 
factor-deprived media supplemented with 2% FCS for at least 24 hours. Cells were 
then seeded at 5x104 per upper chamber and treated ± VEGF (20ng/ml, positive 
control) and/or CathD (50ng/ml) and in the presence or absence of ERK1/2 and/or 
AKT inhibitors at their given concentrations (Table 1). Negative controls received 
carrier alone. After 6 hours incubation at 37oC, the bottom chambers were washed, 
followed by addition of cell dissociation solution/calcein AM for a further hour to label 
and detach migrated cells.  Fluorescence in the bottom wells was read at 485 nm 
excitation and 520 nm emission. 
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2.6. Statistical analysis 
Data are expressed as mean ± standard deviation (SD) and analysed using Mann-
Whitney U test. A p value of less than 0.05 was considered statistically significant. For 
all data, n represents the number of wells or dishes tested under each condition and 
also the results from at least two primary cell populations.  
3. Results 
3.1. CathD induces proliferation of HOMECs 
It is now recognised that during growth tumours secrete growth factors into their  
microenvironment that activate normally relatively quiescent ECs, inducing 
proliferation, migration and ultimately new vessel formation which ensures a nutrient 
supply for the growing tumour. We have previously reported that CathD is secreted by 
EOC cells and since CathD has been reported to be involved in angiogenesis [45], 
initial studies examined the dose dependent (20, 50 and 80 ng/ml) proliferative effects 
of CathD on HOMECs. The range of concentration was selected based on a 
concentration 58ng/ml that was detected in the peritoneal fluid of women with 
endometriosis [46]. Additionally, previously a publication from our laboratory 
suggested that the EOC cell line SKOV3 secretes 14ng/ml in to the conditioned media. 
50ng/ml CathD induced a significant increase in HOMEC proliferation after 72 hours 
(147.0±25.8% vs control, [100%], p=<0.001, n = 20; Fig. 1), and thus this concentration 
was used for all further experiments. 
 
3.2. CathD induces HOMEC proliferation via a non-proteolytic mechanism 
We next performed a series of experiments to investigate whether mature CathD 
enhances HOMEC proliferation in a manner dependent on its proteolytic activity. Initial 
studies examined whether CathD was proteolytically active in the cell culture 
conditions studied.   Preliminary studies confirmed that the pH of cell growth media in 
both the presence and absence of CathD remained at between pH 7.12 and 7.34 even 
over 72 hours of cell culture (Table 2). Using a fluorogenic substrate ( Mca-Gly-Lys-
Pro-Ile-Leu-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2) CathD enzymatic activity was 
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then tested over a range of pHs from 3 to 7.6 (Supplementary data and Fig. 2a) which 
included the published optimum pH for proteolytic activity (pH 3.5-4) and the pH 
neutral conditions confirmed above in cell culture (pH 7-7.6). CathD activity peaked at 
pH4 with no activity above control levels observed at pH 7-7.6.  Indeed, substrate 
hydrolysis was approximately 10 fold greater at pH4 vs pH7 (Fig. 2a), confirming that 
CathD is proteolytically active at its optimum pH. When co-incubated with pepA (1 
μmol/l), a well-known inhibitor of CathD-proteolytic activity, CathD-mediated cleavage 
of the substrate was completely inhibited at pH 4 confirming the effectiveness of the 
inhibitor (Fig. 2a) 
 
 
Fig. 2b demonstrates that CathD-induced proliferation of HOMECs was not inhibited 
by pepA over a range of concentrations including 1 μmol/l which fully inhibited the 
enzymatic activity of CathD above (Fig. 2a). The data presented in Fig. 2c confirm that 
pepA was not cytotoxic to HOMECs at any of the concentrations used i.e. between 
0.1μmol/l and 10 μmol/l.  
 
These data combined indicate that CathD is not proteolytically active in the assay 
conditions studied and that the proliferative effect of CathD in HOMECs is not the 
result of its proteolytic activity but rather via a non-proteolytic mitogenic mechanism. 
 
3.3. CathD activates proliferative kinase ERK1/2 and AKT (S473) 
 
If CathD exerts its mitogenic in HOMECs via a non-proteolytic mechanism this raises 
the possibility that the protein acts as an extracellular ligand, interacting with an, as 
yet unknown, receptor to activate intracellular signalling pathways.  This was initially 
investigated using a proteome-profiler phosphokinase array as a screening tool. 
Several kinases were identified to be phosphorylated in HOMECs during CathD 
treatment for 4 minutes. These included the known cell proliferative kinases ERK1/2 
and AKT which demonstrated a 3-fold and 2.5-fold increase in phosphorylation 
respectively, during CathD treatment compared to control (Fig. 3a).  
 
In order to confirm this initial screen, a cell-based ELISA was carried out with 4 and 
10 minutes incubation with CathD and VEGF, where VEGF was a positive control. 
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After 4 minutes treatment with CathD, there was a ~1.8-fold and ~1.5-fold increase in 
ERK1/2 and AKT phosphorylation relative to the total ERK1/2 and AKT levels 
respectively and compared to control (untreated) (Fig. 3b, d). However, after 10 
minutes incubation, phosphorylated levels of both ERK1/2 and AKT reduced to the 
basal level observed in untreated cells (Fig. 3c, e). Interestingly, although CathD-
induced ERK1/2 phosphorylation was transient, VEGF-induced ERK1/2 
phosphorylation was maintained for at least 10 minutes.  
 
The validity of the cell based ELISA kit was verified using known inhibitors of ERK1/2 
and PI3K/AKT. Pre-incubation with non-toxic concentrations (determined during 
preliminary investigations and based on cell morphology, data not shown) of MEK1/2 
inhibitors U0126 (10 μmol/l) and PD 98059 (25 μmol/l) totally abolished the CathD 
(and VEGF) induced increase in phosphorylation (Fig. 4a, b). Similar results were 
observed in the Akt ELISA using LY294002, a PI3K inhibitor and MK2206, a selective 
AKT inhibitor (Fig. 4c, d). For instance, in the presence of LY294002, CathD-induced 
levels of phosphorylated AKT reduced from ~1.7-fold to 0.4-fold (Fig. 4c). In the case 
of MK2206, levels of phosphorylated AKT decreased from 1.6-fold to 0.5-fold (Fig. 4d). 
This indicates that both drugs inhibit the PI3K/AKT pathway in HOMECs. 
 
3.4. CathD-induced HOMEC proliferation is mediated via ERK1/2 pathway, and 
not AKT 
 
The data presented above raise the possibility that CathD-induced HOMEC 
proliferation involves the activation of ERK 1/2 and Akt. Indeed, both ERK 1/2 
inhibitors, U0126 and PD 98059, significantly reduced CathD-stimulated proliferation 
to levels equal to or below control levels. For example, at 10 µM of U0126 and 25 µM 
of PD98059, cell proliferation decreased to 103.1±8.8% (n=8) and 74.2±4.8% 
compared to CathD (140.6±17.9%, p<0.001, n=20; Fig. 5a, b), all normalised to 
control. A similar observation was made in HOMECs treated with CathD in the 
presence of the PI3K inhibitor LY294002 (108.9±7.6% vs 146.9±9.9% CathD-only 
treatment, both normalised to control; Fig. 5c) but not the AKT inhibitor MK2206 (Fig. 
5d; discussed later). Together, these data suggest that CathD induces HOMEC 
proliferation via a non-proteolytic mechanism that involves activation of intracellular 
pathways downstream of ERK1/2 phosphorylation and possibly PI3K. 
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3.5. HOMEC migration is induced by CathD treatment via both the ERK1/2 and 
AKT pathways 
 
Endothelial cell migration is another key step in tumour-angiogenesis. In an initial 
experiment, CathD significantly increased HOMEC migration by 174.9±52.9% 
(p>0.001, n = 10; data not shown) compared to control (100%). This prompted an 
investigation into the downstream signalling cascades. Inhibitors of both ERK1/2 and 
AKT completely abolished CathD-induced HOMEC migration to basal levels observed 
in control, untreated wells. For instance, in the presence of U0126 and PD98059, 
CathD-induced HOMEC migration reduced to 91.8±7.9% (n=7) and 99.2±9.9% (n=7; 
Fig. 6a) respectively, compared to CathD treatment alone (135.7±26.4%, p<0.001, 
n=12), all expressed as percentage of control (100%). In the presence of the PI3K/AKT 
inhibitors LY294002 and MK2206, CathD-induced HOMEC migration was reduced to 
92.9±46.3% (n=6) and 105.6±45.8 (n=6; Fig. 6b.) respectively, compared to CathD 
treatment (180.0±65.6%, p<0.001, n=12), all expressed as percentage of control 
(100%). These data combined with the ELISA data (Figure 3.9), suggest that CathD 
induces HOMEC migration via a pathway that requires activation of both the ERK1/2 
and AKT(S473) pathways. 
 
 
4. Discussion 
 
Treatment of ovarian cancer remains a significant clinical challenge due to late 
diagnosis and limited effective treatment options for advanced metastatic disease.  
Anti-angiogenic treatment strategies targeting VEGF have proved disappointing and 
indeed we have previously reported that angiogenesis occurring in the omentum 
during metastasis of EOC may occur independently of VEGF signalling.  Additionally, 
we showed that CathD is secreted from EOC cells and has pro-angiogenic effects on 
disease relevant omental ECs i.e. induced migration. These observations raised the 
possibility that the pro-angiogenic effects of CathD may contribute to the robust 
angiogenesis observed during EOC metastasis to the omentum.  However, the full 
effect of CathD on HOMECs and the mechanisms by which it acts to induce these 
11 
 
cellular changes is unknown.  Here we demonstrate for the first time that CathD 
induces significant proliferation and migration in human microvascular endothelial 
cells and that these effects are not dependent on the proteolytic activity of the enzyme. 
Further to this we also demonstrate that CathD induced HOMEC proliferation via 
activation of the ERK1/2 pathway and migration via both ERK1/2 and AKT pathways.  
These data support the hypothesis that CathD secreted from EOC metastasising to 
the omentum contributes to angiogenesis in the growing secondary omental lesion.   
 
CathD is an aspartic endopeptidase involved in degrading unfolded, dysfunctional self- 
or foreign- proteins in lysosomes and phagosomes [11]. The protein is synthesised in 
rough endoplasmic reticulum as preprocathepsin D and is cleaved and further 
modified into procathepsin D (pCathD) that is targeted and transported to intracellular 
vesicles such as lysosomes and phagosomes by both mannose-6-phosphate receptor 
(M6PR) dependent and independent pathways [14]. pCathD is converted to its active 
mature form CathD in the acidic environment of lysosomes. Although CathD is a 
lysosomal enzyme and its enzyme activity is usually regulated within the acidic 
compartment of lysosomes, it has also been shown to be enzymatically active extra-
lysosomally under normal physiological conditions at neutral pH e.g. CathD has been 
shown to be involved as a key mediator of induced apoptosis [47-51].  We therefore 
examined whether CathD is acting via a proteolytic- or non-proteolytic mechanism   to 
induce proliferation in HOMECs. Investigation of the pH of cell culture media 
throughout the course of the proliferation assays confirmed that the pH was 
consistently above 7 i.e. outside of the optimum published range of CathD activity; 
suggesting that proliferation was not due to the enzymatic activity of the enzyme.  This 
was further confirmed using a known inhibitor of CathD proteolytic activity, pepA. Cell 
proliferation was assessed with or without CathD in the presence or absence of 
increasing concentrations of pepA. The data indicate that in the presence of a range 
of concentrations of pepA, CathD was still able to induce proliferation in HOMECs. 
Next, to confirm the inhibitory effects of pepA we examined CathD activity using a 
CathD-specific substrate at an array of pHs.  At pHs where CathD was active i.e. pH4 
pepA completely inhibited its proteolytic activity. The enzyme was not proteolytically 
active at pH7.  Thus, our data indicate that not only is CathD not proteolytically active 
at the pH observed in cell culture media, but also that the inhibitor used i.e. pepA fully 
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abolishes CathD activity in conditions where the enzyme is active. Taken together 
these data indicate, for the first time, that CathD acts as a mitogen via a non-proteolytic 
mechanism in HOMECs i.e. acts as an extracellular ligand.  
It is well known that several downstream signalling pathways are activated following 
treatments with mitogenic factors. Since it appears that CathD induces cell 
proliferation as a protein receptor ligand for HOMECs, we hypothesised that 
proliferative intracellular downstream signalling pathways may be activated in 
HOMECs following CathD treatment. Initially, we investigated activation of possible 
downstream proliferative kinases in these cells using a human proteome profiler. This 
kit identifies the phosphorylation status of 43 intracellular kinases and showed that 
ERK1/2 and AKT phosphorylation levels were upregulated in HOMECS following 
CathD treatment, compared to control. These data were confirmed using live cell-
based ELISAs. The relationship between activation of these pathways and the 
proliferative effects of CathD were confirmed using well-known MEK1/2 (upstream of 
ERK1/2) inhibitors (U0126 and PD98059) and PI3K/AKT kinase inhibitors (LY294002 
and MK2206). ELISA data confirmed the effectiveness of the inhibitors at significantly 
reducing ERK1/2 and AKT phosphorylation respectively to baseline levels. Next, we 
showed that the two MEK1/2 inhibitors reduced or abolished CathD induced HOMEC 
proliferation over 72 hours. A similar observation was also made in HOMECs treated 
with the PI3K inhibitor LY294002 but not with the selective AKT inhibitor MK2206. 
However, the PI3K/AKT pathway inhibitor used,  LY294002, is known to cross-react 
with the ERK1/2 pathway where it inhibits ERK1/2 phosphorylation [52]. Thus, it is 
possible that LY294002 in fact inhibited the ERK1/2 pathway and reduced HOMEC 
proliferation, and that AKT is not involved in the induction of cell proliferation as the 
specific AKT inhibitor failed to reduce the proangiogenic effect in HOMECs. Taken 
together, these data suggest that the ERK1/2 pathway is involved in the induction of 
HOMEC proliferation by exogenous CathD. 
Since CathD was also shown to induce migration in these cells, the downstream 
signalling cascades activated during this pro-angiogenic response were also 
investigated. Since, it has been shown in several studies that activated ERK1/2 and 
AKT pathways are involved in cell migration [53-55] the involvement of these kinases 
in CathD induced HOMEC migration was examined. Interestingly, we show for the first 
time that both kinases are involved in the CathD-induced migration in HOMECs.  
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Taken together our data suggest that CathD may be an important pro-angiogenic 
factor in in the omental metastasis of EOC. Indeed, it is now well recognised that 
pCathD/CathD is overexpressed and hyper-secreted in several different cancer types, 
including ovarian cancer. Over-expression of CathD has been established as a poor 
prognostic marker in breast cancer patients and was shown to induce tumour invasion 
into surrounding tissue [19]. It has been reported that pCathD is overexpressed by, 
and hyper-secreted from oestrogen-treated MCF7 breast cancer cells and that the 
secreted protein acts as a protein ligand to  stimulate MCF7 cell  growth  via an 
autocrine mechanism [41]. While secreted-pCathD is generally considered to be 
proteolytically inactive, it has been proposed that the acidic pH in the tumour 
microenvironment promotes the conversion pCathD into mature, biologically active 
CathD [56]. This was supported by data indicating that pCathD, collected from tumour-
conditioned media, became auto-activated if the pH was lowered and was 
subsequently able to degrade ECM proteins and release growth factors such as bFGF, 
steps important for cancer cells to invade surrounding tissue [22, 57]. 
 
Evidence for a role of CathD in angiogenesis has been increasing. An early study  
performed in 3Y1-Ad12 tumour xenografts mice using both catalytically active and 
inactive (mutated) forms of CathD suggested both a proteolytic and mitogenic role for 
CathD [36]. The underlying mechanism of CathD induced angiogenesis, however, was 
not elucidated. CathD has also been shown to induce blood vessel formation in the 
CAM model and a role for CathD in angiogenesis was further suggested by the 
observation that migration of HUVECs and in vitro angiogenic tube formation were 
increased when cells were treated with active pure CathD [34]. CathD was 
proteolytically active in these experiments as complete inhibition of angiogenesis, tube 
formation and migration was achieved by addition of pepA [34]. Proteolytically active 
CathD has also been suggested to induce angiogenesis in breast cancer by cleaving 
and releasing ECM-bound pro-angiogenic bFGF [22]. In contrast it has also been 
suggested that CathD activity may be anti-angiogenic. For instance, pCathD secreted 
by prostate cancer cells was shown to have a possible role in generating angiostatin 
via proteolysis—a specific inhibitor of angiogenesis in vitro as well as in vivo [25].  
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Due to the heterogeneity of EC morphology, proteomic properties and functionalities 
in different vascular beds it is important to study cellular responses in disease relevant 
ECs. Using disease-relevant HOMECs we show for the first time that exogenous 
CathD induces EC proliferation and migration in a proteolytic-independent manner. 
The proliferative effect is downstream of activation of the ERK1/2 pathway and the 
migratory effect is via activation of both the ERK1/2 and AKT pathways.  Given the 
array of angiogenesis-associated proteins secreted by tumour cells and the complexity 
of the angiogenic process it is likely that EOC-induced omental angiogenesis is driven 
by the interplay of a range of proangiogenic factors, of which CathD is only one 
element.  However, a greater understanding of the mode of action of each individual 
pro-angiogenic factor is required to fully dissect this process. We believe that our data 
highlight CathD as one of these proangiogenic factors which may be a promising target 
in anti-angiogenic therapy in the treatment of ovarian cancer metastasis. 
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Table 1. Concentrations of treatments added to cell proliferation assay. 
Treatments Purpose Concentration(s) Source 
VEGF Positive control  20 ng/ml Peprotech (London, UK) 
CathD Treatment 20, 50, 80 ng/ml Sigma-Aldrich (Poole, 
UK) 
pepA CathD inhibitor 0.1, 1, 2.5, 5 and 10 
µmol/l 
Sigma-Aldrich (Poole, 
UK) 
U0126 MEK/ERK1/2 
inhibitor 
10 µmol/l Stratech (Suffolk, UK) 
PD 98059 MEK/ERK1/2 
inhibitor 
25 µmol/l Stratech (Suffolk, UK) 
LY294002  PI3K inhibitor 25 µmol/l Stratech (Suffolk, UK) 
MK2206  AKT inhibitor 5 µmol/l Stratech (Suffolk, UK) 
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Table 2: pH of cell culture media and supernatant during CathD treatment. Cells 
were seeded in 6 well plates and treated with or without CathD (50ng/ml) for 24, 48 
and 72 hours. Media were collected and their pH was measured. n.d. denotes not 
determined. 
 
  pH  
 0h 24h 48h 72h 
Basal mv2 7.34 n.d.  n.d. n.d. 
Untreated n.d. 7.19 7.13 7.12 
CathD  n.d. 7.21 7.13 7.12 
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Fig. 1. Increased proliferation of HOMECs in media supplemented with CathD 
(WST-1 assay). Cells were seeded in 2% gelatin pre-coated 96 well plates at a density 
of 10,000cells/well in starvation media containing 2% FCS. After overnight incubation, 
cells were treated with or without various concentrations of CathD and incubated for 
72 hours. A commercially available WST-1 kit was used to assess cellular proliferation 
based on absorbance using a PHERAstar BMG plate-reader at 450nm. Results are 
mean ± SD and shown as percentage of the control, *p<0.05, ***p<0.001 vs control 
(100%), n=5-20. n.s. denotes not significant. 
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Fig. 2: PepA, an inhibitor of CathD proteolytic activity, does not inhibit CathD-induced 
HOMEC proliferation. a) CathD proteolytic activity is not observed at pH 7. A specific 
fluorogenic substrate (100 nmol/l) was incubated with or without CathD (50ng/ml) and in the 
absence or presence of pepA (1 μmol/l) at pH 4 and 7. Fluorescence signals were measured 
immediately using a SpectraMax plate reader at Ex/Em: 320/393. Control wells contained pH 
buffer and substrate and/or inhibitor. The data are represented as percentage of control. 
**p<0.01 vs control (substrate) (100%); ##p<0.01 vs CathD + substrate (expressed as % of 
control), n=3. b + c) Cells were seeded in 2% gelatin pre-coated 96 well plates at a density of 
10,000cells/well in starvation media containing 2% FCS. After overnight incubation, cells were 
treated with or without CathD (50ng/ml) in the presence or absence of various concentrations 
of pepA (as shown above- b) CathD + pepA or c) pepA alone) and incubated for 72 hours. 
WST-1 assay was used to assess cellular proliferation based on absorbance using a 
PHERAstar BMG plate-reader at 450nm. Control wells contained 0.1% DMSO (carrier only). 
Results are mean ± SD and shown as percentage of the control, ***p<0.001 vs control (100%); 
n=8-16. n.s. denotes not significant. 
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Fig. 3. CathD-induced activation of intracellular kinases. a) CathD induces 
phosphorylation of ERK1/2 and AKT(S473) in HOMECs. Phosphorylation status of the 
intracellular kinases was assessed in cell lysates from cells treated with or without 
CathD for 4 minutes. The results of 1 minute exposure are expressed as mean dot 
density (arbitrary units). The relative expression of specific phosphorylated proteins 
was determined following quantification of scanned images. b-e) CathD induces 
phosphorylation of ERK1/2 and AKT in HOMECs. Cells were seeded in 2% gelatin 
pre-coated 96 well plates at a density of 10,000cells/well in starvation media 
containing 2% FCS. After overnight incubation, cells were treated with or without 
50ng/ml of CathD or 20ng/ml of VEGF (positive control) and incubated for 4 or 10 
minutes. ERK1/2 (b, c) and AKT (d, e) phosphorylation was examined after 4 minutes 
(b, d) and 10 minutes (c, e) treatments. Commercially available cell-based ELISAs 
were used for the determination ERK1/2 and AKT(S473) phosphorylation level.  The 
ELISA experiments were carried out on two cell batches. The data is represented by 
fold change in phosho-ERK1/2/AKT relative to total ERK1/2/AKT (compared to 
control). Results are mean ± SD, *p<0.05, **p<0.01, ***p<0.001 vs control (dotted 
lines); n=4-6. n.s. denotes not significant. 
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Fig. 4. ERK1/2 and AKT inhibitors reduce ERK1/2 and AKT phosphorylation 
respectively in intact HOMECs. After overnight starvation in media supplemented 
with 2% FCS, cells were pre-incubated with the ERK1/2 inhibitors a) U0126 (10 μmol/l) 
and b) PD98059 (25 μmol/l) or PI3K/AKT inhibitors c) LY294002 (25 μmol/l) and d) 
MK2206 (5 μmol/l) for (a + b) 20-30 minutes or (c + d) 2.5 hours, and then co-treated 
with or without 50ng/ml of CathD or 20ng/ml of VEGF for 4 minutes. Commercially 
available cell-based ELISAs were used for determination of ERK1/2 phosphorylation 
level.  The data is represented as fold change in phosho-ERK1/2 relative to total 
ERK1/2 (compared to control). Results are mean ± SD, *p<0.05, **p<0.01 vs control 
(1-fold), #p<0.05 vs VEGF/CathD (normalised to control), n=4. The dotted lines 
represent basal level (control) of phosphorylation status in untreated HOMECs. 
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Fig. 5. CathD-induced HOMEC proliferation is mediated via activation of the 
ERK1/2 and PI3K pathways, but not AKT pathway. After overnight starvation in 
media supplemented with 2% FCS, cells were treated with or without CathD (50ng/ml) 
and in the absence or presence of a) U0126 (10 μmol/l), b) PD98059 (25 μmol/l), c) 
LY294002 (25 μmol/l) and d) MK2206 (5 μmol/l) and incubated for 72 hours. WST-1 
assay was used to assess cellular proliferation. Results are mean ± SD and shown as 
percentage of the control, n.s., ***p<0.001 vs control (100%), ###p<0.001 vs CathD 
(normalised to control 100%), n=8-20. n.s. denotes not significant. 
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Fig. 6. CathD induces HOMEC migration via activation of the a) ERK1/2 and b) 
AKT pathways. Pre-treated (with corresponding kinase inhibitor) HOMECs were 
seeded in the upper transwell chamber and treated with or without CathD (50ng/ml) in 
the absence or presence of a) U0126 (10 μmol/l) and PD98059 (25 μmol/l) or b) PI3K 
and AKT inhibitors LY294002 (25 μmol/l) and MK2206 (5 μmol/l), respectively in media 
containing 0.5% FCS. The lower well contained correspondent treatments. After 6 
hours, migrated cells were stained with calcein AM and fluorescence was quantified 
using a FLUOstar plate reader at Ex/Em: 485/520. Results are mean ± SD and shown 
as percentage of the control, n.s., *p<0.05, **p<0.01, ***p<0.001 vs control (100%), 
#p<0.05, ###p<0.001 vs CathD (normalised to control (100%)), n=6-12. n.s. denotes 
not significant.  
 
 
26 
 
 
 
 
 
Fig. 7. A summary of CathD -induced activation of the ERK1/2 and AKT 
pathways, and cellular functions in HOMECs.  CathD non-proteolytically activates 
a cell surface receptor, possibly a receptor tyrosine kinase, which leads to an increase 
in phosphorylation of ERK1/2 and AKT. The MEK/ERK1/2 inhibitors U0126 and 
PD98059 significantly reduce these cellular functions by inhibiting ERK1/2 
phosphorylation. Both PI3K inhibitor LY294002 and AKT inhibitor MK2206 inhibit 
phosphorylation of AKT at Ser473 (S473) in CathD-treated HOMECs. However, only 
LY294002, but not MK2206, inhibits CathL-induced HOMEC proliferation, suggesting 
a cross-reaction of PI3K inhibitor LY294002 with the ERK1/2 pathway. Interestingly, 
both PI3K and AKT kinases are activated in CathD-induced HOMEC migration, which 
was reduced in the presence of both LY294002 and MK2206. 
 
